🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against drug-resistant strains of the bacteria, according to scientists.

A Global Public Health Issue

Gonorrhoea infections are increasing around the world, with estimates suggesting in excess of 82 million infections annually. Particularly high rates are observed in Africa and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely step in the face of increasing worldwide cases, escalating drug resistance and the highly restricted therapeutic options presently on offer.”

Health officials are increasingly worried about the increase in treatment-resistant strains. The global health body has listed it as a "high-priority threat". Recent surveillance showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Recent Treatment Options Receive Authorization

One new antibiotic, alternatively called a brand name, was cleared by the American regulatory agency in December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Researchers hope that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GSK, was also approved in concurrent days. This treatment, which is also used to treat UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment stemmed from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This approval signifies a huge turning point in the therapy of superbug gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Clinical Trial Data and Worldwide Availability

Based on results published in a major medical journal, the new drug successfully treated over nine in ten of uncomplicated infections. This places it at an similar efficacy with the existing first-line therapy, which uses a dual-drug approach. The study enrolled nearly 1,000 participants from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its collaboration, the non-profit has the rights to register and commercialise the drug in a wide range of regions with limited resources.

Clinicians treating patients have voiced hope. The availability of a single-dose, oral treatment such as this is seen as a "revolutionary step" for gonorrhoea control. This is viewed as crucial to reduce the burden of the disease for patients and to halt the transmission of highly drug-resistant gonorrhoea worldwide.